CYP19A1 and breast carcinoma: Estrogen lack is considered a risk factor for lipid abnormalities and atherosclerosis in post-menopausal women (39) and aromatase inhibitor therapy in women with breast cancer may increase LDL and reduce HDL cholesterol, rising the cardiovascular risk in this population (43).